Funding for this research was provided by:
Oklahoma Medical Research Foundation
Children's Hospital Foundation
National Institutes of Health (1S10OD023508, P30 CA225520, P20 GM103639)
Received: 30 July 2020
Accepted: 29 October 2020
First Online: 10 November 2020
Ethics approval and consent to participate
: Human cells used in this study were obtained under a protocol (M-1608) approved by the Institutional Review Board (IRB) at Hospital Sant Joan de Déu (Barcelona, Spain). Acquisition of human tissue samples were obtained after signed informed consent from legal guardians. The Institutional Animal Care and Use Committee (IACUC) of the Oklahoma Medical Research Foundation approved the animal protocol [CitationRef removed–CitationRef removed].
: Not applicable.
: RAT holds patents for OKN-007 as a treatment for gliomas. The remaining authors have declared no competing interests.